Skip To Content
Volunteer Advocate

News

All media inquiries can be directed to mediarelations@cysticfibrosis.ca or by calling 1-800-378-2233.


Impact of COVID-19 on Cystic Fibrosis Patients Examined in Global Report
November 9, 2020

TORONTO (November 9, 2020) - A new study recently published in the Journal of Cystic Fibrosis suggests that although the outcomes of COVID-19 in individuals living with cystic fibrosis (CF) were not as severe as originally feared, there is still a range of possible clinical outcomes following a diagnosis, and an indication that the novel coronavirus is not a benign virus for people with cystic fibrosis.

Read More
Life-changing treatment, Trikafta, is coming to Canada
November 9, 2020

TORONTO (November 9, 2020)– Today the cystic fibrosis story is significantly changing, with a long-awaited transformational therapy now in sight for Canadians living with the disease. Cystic Fibrosis Canada has received information that a  decision has been made by the manufacturer to bring new CF medicines to Canada.

Read More
Cystic Fibrosis Canada Hosts Historic Emergency All Party Meeting on Access to Trikafta
October 23, 2020

Approximately 30 Members of Parliament and Senators from all parties today met with cystic fibrosis advocacy groups to discuss how to get Canadians access to the breakthrough cystic fibrosis (CF) drug Trikafta in an historic all party meeting that was hosted by Cystic Fibrosis Canada.

Read More
Cystic Fibrosis Canada joins inter-charity coalition to “Protect Our Access”
October 21, 2020

TORONTO, October 21, 2020— Cystic Fibrosis Canada is working with health charities and patient groups to launch a campaign to ensure Canadians are not denied access to breakthrough drugs, like the cystic fibrosis (CF) drug Trikafta. The campaign aims to influence policy and increase public awareness of the proposed changes to the Patented Medicine Prices Review Board (PMPRB) guidelines and their impact on Canadians.

Read More
Position on barriers to access to break-through CF drug Trikafta in Canada
September 22, 2020

Introduction: Cystic Fibrosis Canada and the cystic fibrosis community, including more than 50 cystic fibrosis clinicians, have been reaching out to Members of Parliament calling for change as part of our relentless efforts to get immediate access to the break-through cystic fibrosis drug Trikafta and avoid preventable deaths among the Canadian cystic fibrosis community.

Read More
OPEN LETTER to elected officials and policymakers in Canada’s drug review and reimbursement system from cystic fibrosis clinicians
September 17, 2020

An open letter from Canadian cystic fibrosis clinicians calling upon the government to take action for Trikafta now. 

Read More
Clinical Trials Network Now Covers More Than 60% of Canadian CF Population
September 4, 2020

TORONTO, September 4, 2020Cystic Fibrosis Canada is proud to announce the expansion of the Cystic Fibrosis Canada Accelerating Clinical Trials Network (CF CanACT) from six sites across Canada, to ten.

Read More
New Research Shows 15% Reduction in Cystic Fibrosis Deaths by 2030 If Trikafta is Made Available Now
August 24, 2020

TORONTO, August 24, 2020 - Cystic Fibrosis Canada is imploring the government to take action given new research published today that demonstrates that access to the cystic fibrosis (CF) drug Trikafta in 2021 would result in profound health improvements for people living with cystic fibrosis who take the drug. By 2030 Trikafta could reduce the number of people living with severe lung disease by 60% and reduce the number of deaths by 15%.

Read More
Cystic Fibrosis Canada Partners with Evolve Fitness
July 28, 2020

TORONTO (July 28, 2020) – Cystic Fibrosis Canada is pleased to announce its year-long virtual partnership with Nova Scotia-based fitness centre, Evolve Fitness. Members of the cystic fibrosis (CF) community who sign up for a $30(CAD) monthly membership for online fitness classes will see $10 (CAD) of their membership fees donated to Cystic Fibrosis Canada every month, for a year.

Read More
pan-Canadian Pharmaceutical Alliance agrees to negotiate for access to life-changing cystic fibrosis treatments
June 12, 2020

TORONTO (June 12, 2020) – Today, Canadians with cystic fibrosis are one step closer to gaining access to a suite of life-changing treatments for cystic fibrosis as the pan-Canadian Pharmaceutical Alliance (pCPA) and the drugs’ manufacturer, Vertex Pharmaceuticals, have agreed to begin negotiations.

Read More